Synovial Sarcoma Market
Aug 12, 2024
TECELRA Approval for Synovial Sarcoma Treatment – A Ray of Hope
Adaptimmune Therapeutics and patients waiting for synovial sarcoma treatment witnessed a historic moment at the start of this month. After over ten years without new synovial sarcoma treatments, a groundbreaking, first-in-class cell therapy, TECELRA (afamitresgene autoleucel) has been approved by the FDA. This a...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
